I-Drug ye-HIV ihanjiswe kwi-Option First Line Line e-US
I-Tivicay (dolutegravir) yi- integrase inhibitor -yilisi ye- antiretroviral usetyenziso ekwenzeni unyango lwe-HIV. Kwakuyesibili eklasini ye-integrase inhibitors ukuba ivunyiwe yi-US Food and Drug Administration (FDA).
I-Tivicay inikwe ilayisenisi ye-FDA ngo-Agasti 12, 2013, ukusetyenziswa kubantu abadala kunye nabantwana abaneminyaka eli-12 okanye ngaphezulu abala ubuncinane ubunzima be-88 lbs (40kg) kwaye abazange baphathwe ngaphambili nge-integrase inhibitor.
(I-Tivicay okwamanje ayivunyelwanga kubantwana abangaphantsi kwe-12 nangona i-Phase III iilingo zonyango ziyaqhubeka ukuvavanya ukhuseleko kunye nokusebenza kwayo kwiqela elidala.)
I-Tivicay nayo iyinxalenye yesilwanyana esisisigxina , esisisigxina se-dose, i- Triumeq , esibandakanya izidakamizwa abacavir kunye ne-lamivudine. I-Triumeq yavunywa yi-FDA ngo-Agasti 22, 2014.
Iingqwalasela zophando zeKliniki
Uvavanyo lwe-VIKING-3 lubonise ukuba iTivicay yayiphumelele kwi-63% yezigulane zabantu abadala abanokuchasene neeklasi ezininzi zezidakamizwa ze-HIV, kubandakanywa ne-integrase inhibitors i-Isentress (ratelgravir) kunye ne-elvitegravir (efunyenwe kwipilisi enye, i-dose edibeneyo yezidakamizwa, iStribild ) .
ISIFUNDO SINGLE sibonakalise ukuba izigulane zaseTivicay zineziganeko ezincinane zokuyeka ukusukela ngenxa yeziphumo ezingekho mthethweni kuneAriprip (tenofovir + emtricitabine + efavirenz). Emva kweeveki ezingama-48, i-2% yezifundo kwi-Rivicay-based based regimen unyango oluyekiweyo ngokumalunga no-10% walabo bafumana i-Atripla.
Isistim
- Abantu abadala: 50mg tablet, kanye rhoqo
- Abantu abadala abane-integrase-inhibitor enxulumene no-50mg tablet, kabini imihla ngemihla
- Abantwana abali-12 nangaphezulu (ubunzima be-88 lbs / 40kg okanye ngaphezulu): 50mg tablet, kanye ngosuku
Ukongezelela, kubantwana abalawulwa ngokusemthethweni uSustiva (efavirenz), Aptivus (tipranavir) + i-Norvir (ritonavir), i-Lexiva (fosamprenavir) + ne-Norvir (ritonavir), okanye i-rifampin, i-doivicay dose yi-50mg, kabini imihla ngemihla.
Akusaziwa ukuba i-Tivicay isebenzayo kubantwana abane-integrase-inhibitor echaphazelekayo.
Ulawulo Lweziyobisi
I-Tivicay ingathathwa kunye okanye ngaphandle kokutya, kwaye nayiphi na imini yosuku.
Iziphumo eziPhakathi
Iziphumo eziqhelekileyo eziqhelekileyo (ezivela kwi-2% okanye ngaphantsi kwamatyala) zi:
- Ukungabikho
- Intloko
- Utywala
- I sizathu
Ukusebenzisana kwezidakamizwa okanye ukungahambisani
I-Tikosyn (dofetilide), esetyenziselwa unyango lwe-arrhythmia (intliziyo engavumelekanga), iyaphikiswa ukuba isebenzise neTivicay.
Ukuze ugweme ukusebenzisana kweziyobisi, ucebise ugqirha wakho ukuba uthatha nawaphi na mayeza alandelayo okanye amayeza:
- Iyeza-antiretroviral: Sustiva (efavirenz), Intelence (etravirine), i-Viramun (i-nevirapine), kunye ne-Lexiva (fosamprenavir) + ne-Norvir (ritonavir), okanye i-Aptivus (tipranavir) + ne-Norvir (ritonavir)
- Amachiza okulwa ne-anti-seizure: Trileptal (oxcarbazepine), i-Dilantin (phenytoin), iPhenytek (phenytoin), i-Luminal (phenobarbital), okanye i-carbamazepine-based based drugs njengeCarbatrol, Equetro, Tegretol, Teril, okanye Epitol
- I-Rifampin-based antibiotics: Rifadan, Rifater, Rifamate, Rimactane
- I-Metformin-based based diabetes: I-Fortamet, i-Glucophage, i-Glumetza, i-Riomet
- ISt John's Wort
Ukuqwalasela
- Izigulane ezithintekayo emva kokuqala kweTivicay kufuneka zidibanise nodokotela ngokukhawuleza . Unyango kufuneka ugqitywe kwaye unyango lwezokwelapha lufunwa ukuba i-rash ihamba kunye neentlungu, umsizi okanye intlungu ehlanganyelweyo, i-blisters okanye izilonda, ubomvu okanye ukuvuvukala kwamehlo, ukuvuvukala ubuso okanye umlomo, okanye iingxaki zokuphefumla. Izigulane eziye zafumana ukuphendulwa kwe-hypersensitive kwi-Tivicay akufanele ziphinde zijongelwe kunye neziyobisi emva kokusombulula iimpawu.
- I-Tivicay ifanele ithathwe iiyure ezimbini ngaphambi kweyure okanye ezintandathu emva kokuthatha i-aluminium okanye i-magnesium ene-antacids okanye i-laxatives, izongezo zetsimbi, i-calcium supplement, imithi enxilisiweyo okanye i-Carafate (sucralfate) esebenzisa unyango lwezilonda zamadoda.
- Yazisa ugqirha wakho nayiphi na imeko yesibindi onokuyenza ngaphambi kokuba uqale iTivicay. Kukho ubuncipheko obangela ukwanda kweengxaki zesibindi kwabanye, ngakumbi kubantu abane-hepatitis B (i-HVB), i- hepatitis C (i-HCV) , okanye ukungasebenzi kwesibindi. Iimvumi ze-enzyme kufuneka zihlolwe rhoqo njengenxalenye yesifo somntu esenza rhoqo i-Tivicay.
> Imithombo:
ILayibrari yeSizwe ka-US yamayeza. "I-TIVICAY (i-dolutegravir sodium) ithebulethi, icwecwe ifilimu." EBethesda, eMaryn; kuhlaziywa ngoAgasti 2013.
ViiV Healthcare. "I-ViiV Healthcare ifumana imvume ye-FDA ye-Triumeq." ELondon, eNgilani; ukukhutshwa kwenkcazelo ekhutshwe nge-22 Agasti 2014
Walmsley S.; Antela, A .; Clumeck, N; okqhubekayo. "I-Dolutegravir (i-DTG; S / GSK1349572) + abacavir / lamivudine kanye ngokuphindaphindiweyo i-tenofovir / emtricitabine / efavirenz: iziphumo zeeveki ezingama-48 - ISINGLE (ING114467)." INgqungquthela ye-Interscience yama-52 kwi-Antimicrobial Agents kunye ne-Chemotherapy. Esan Francisco; Septemba 9-12, 2012; Abstract H-556b.
Nichols, G .; Grossberg, R .; Lazzarin, A .; okqhubekayo. Umsebenzi we-Antitiviral we- Dolutegravir kwiZifundo kunye nokusilela kwiRegram ye-Integrase Inhibitor-based Based: Iveki 24 Iziphumo zeSigaba 3 ezivela kwi-VIKING-3. " I-Congress ye-11 yamazwe ngamazwe kwiNyango yamayeza e-HIV (HIV11). EGlasgow, Scotland; Novemba 11-15, 2012; Abstract O232.